A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2009
11/19/2009	CA2724290A1 Naphthylmethylimidizoles for the treatment of stress urinary incontinence
11/19/2009	CA2724271A1 Therapeutic substituted cyclopentanes
11/19/2009	CA2724262A1 Pyrrolopyridines as kinase inhibitors
11/19/2009	CA2724246A1 Anticancer combination therapy including triciribine
11/19/2009	CA2724232A1 Sulfone compounds which modulate the cb2 receptor
11/19/2009	CA2724219A1 5-[5-[2-(3,5-bis(trifluoromethyl)phenyl)-2-methylpropanoylmethylamino]-4-(4-fluoro-2-methylphenyl)]-2-pyridinyl-2-alkyl-prolinamide as nk1 receptor antagonists
11/19/2009	CA2724216A1 2h- pyrimido [2, 1-b] quinazolin-2-one derivatives and their use as platelet anti-aggregative agents
11/19/2009	CA2724215A1 Carbamoyl derivatives of bicyclic carbonylamino-pyrazoles as prodrugs
11/19/2009	CA2724214A1 Alicyclic carboxylic acid derivatives of benzomorphans and related scaffolds, medicaments containing such compounds and their use
11/19/2009	CA2724213A1 Substituted quinazolines as blood platelet lowering agents
11/19/2009	CA2724206A1 Multiple myeloma treatments
11/19/2009	CA2724191A1 Film-shaped preparation comprising oily substances for oral administration
11/19/2009	CA2724181A1 Imidazoquinazoline derivatives as anagrelide analogues for the treatment of myeloprolific diseases and thrombotic diseases
11/19/2009	CA2724180A1 Substituted quinazolines
11/19/2009	CA2724179A1 Oligonucleotides for treating inflammation and neoplastic cell proliferation
11/19/2009	CA2724173A1 Methods of detecting cells with a disrupted cell membrane, cells infected with a pathogen, dying cells or dead cells
11/19/2009	CA2724172A1 Mono ( iron hydroxypyrone ) and combination ( iron hydroxypyrone and gi inflammation inhibiting agents ) compositions for anaemia or h. pylori infections
11/19/2009	CA2724133A1 Medicine consisting of concomitant use or combination of dpp-iv inhibitor and other diabetic medicine
11/19/2009	CA2724116A1 Glucokinase activators
11/19/2009	CA2724077A1 Amide compound
11/19/2009	CA2724055A1 Glucocorticoid receptor agonist comprising 2,2,4-trimethyl-6-phenyl-1,2 -dihydroquinoline derivatives having substituted oxy group
11/19/2009	CA2724035A1 Substituted quinazolines
11/19/2009	CA2724030A1 Sequential administration of 20,20,21,21-pentafluoro-17-hydroxy-11.beta.-[4-(hydroxyacetyl) phenyl]-19-nor-17.alpha.-pregna-4,9-diene-3-one and one or more progestational hormonesfor treating gynaecological diseases
11/19/2009	CA2724023A1 Salicylate conjugates useful for treating metabolic disorders
11/19/2009	CA2724020A1 Substituted quinazolines and their uses for myeoloprolific and thrombotic diseases
11/19/2009	CA2724009A1 Pulmonary delivery of a fluoroquinolone
11/19/2009	CA2724007A1 Stabilization processes of cation radicals of phenothiazinic compounds, cosmeceutical formulations and methods for skin diseases and disturbances prevention
11/19/2009	CA2724003A1 Novel n-(2-amino-phenyl)-acrylamides
11/19/2009	CA2723989A1 Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy}quinazoline
11/19/2009	CA2723981A1 New compounds 273
11/19/2009	CA2723968A1 Method for efficient exon (44) skipping in duchenne muscular dystrophy and associated means
11/19/2009	CA2723958A1 Substituted quinazolines
11/19/2009	CA2723944A1 Anti-cancer combination therapy
11/19/2009	CA2723938A1 3,5-diamino-6-chloro-pyrazine-2-carboxylic acid derivatives and their use as epithelial sodium channel blockers for the treatment of airway diseases
11/19/2009	CA2723922A1 Purine derivatives further comprising a mercapto-acylamino group as neutral endopeptidase inhibitors
11/19/2009	CA2723909A1 Pharmaceutical product comprising a muscarinic receptor antagonist and a beta2-adrenoceptor agonist
11/19/2009	CA2723858A1 Substituted quinazolines
11/19/2009	CA2723857A1 Substituted quinazolines
11/19/2009	CA2723834A1 Pharmaceutical compositions for the treatment of warts
11/19/2009	CA2723826A1 N- (1, 1, 1, 3, 3, 3-hexafluoro-2-hydroxypropan-2-yl) benzyl-n' -arylcarbonylpiperazine derivatives
11/19/2009	CA2723822A1 Set of antiangiogenic molecules and use thereof
11/19/2009	CA2723768A1 Novel uses of d-mannopyranose derivatives
11/19/2009	CA2723767A1 Novel uses of d-mannopyranose derivatives activating angiogenesis
11/19/2009	CA2723729A1 Oxazolobenzimidazole derivatives
11/19/2009	CA2723727A1 Oxazolobenzimidazole derivatives
11/19/2009	CA2723725A1 Angiotensin ii receptor antagonists
11/19/2009	CA2723649A1 Transnasal anticonvulsive pharmaceutical composition comprising poorly soluble anticonvulsant
11/19/2009	CA2723623A1 Therapeutic agent for pain
11/19/2009	CA2723617A1 Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer
11/19/2009	CA2723465A1 Proteasome inhibitors
11/19/2009	CA2723458A1 Controlled release corticosteroid compositions and methods for the treatment of otic disorders
11/19/2009	CA2723455A1 Lipoprotein lipase-activating compositions comprising benzene derivates
11/19/2009	CA2722578A1 Use of .delta.-amino levulinic acid to treat male infertility
11/19/2009	CA2722418A1 Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors
11/19/2009	CA2722244A1 A solid pharmaceutical formulation
11/19/2009	CA2722158A1 Inhibitors of jnk
11/19/2009	CA2722056A1 Hcv protease inhibitors
11/19/2009	CA2721706A1 3-aminocarbazole compound, pharmaceutical composition containing it and preparation method therefor
11/19/2009	CA2713413A1 Poly aromatic sodium channel blockers
11/18/2009	EP2119792A1 Novel macrolide compound
11/18/2009	EP2119784A2 Method and compositions for cellular reprogramming
11/18/2009	EP2119783A1 Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
11/18/2009	EP2119738A1 Polyethylene glycol derivative
11/18/2009	EP2119720A1 Novel vinblastine derivatives, their preparation, use and pharmaceutical compositions comprising the said derivatives
11/18/2009	EP2119719A1 Thiazepine derivative
11/18/2009	EP2119718A1 Macrocyclic compound
11/18/2009	EP2119717A1 8-[3-amino-piperidin-1-yl]-xanthins, their production and utilisation as DPP IV inhibitors
11/18/2009	EP2119716A1 Aza-bridged-ring compound
11/18/2009	EP2119715A1 Benzimidazole derivative and its use as aii receptor antagonist
11/18/2009	EP2119712A1 Novel methylated catechin and composition containing the same
11/18/2009	EP2119708A1 Tetrahydroquinazoline compounds and their use in preparing medicaments for treating and preventing virosis
11/18/2009	EP2119707A1 Composition for treatment of undifferentiated-type of gastric cancer
11/18/2009	EP2119706A1 Pyridine or pyrimidine derivative having excellent cell growth inhibition effect and excellent anti-tumor effect on cell strain having amplification of hgfr gene
11/18/2009	EP2119705A1 3-Aminocarbozole compound, pharmaceutical composition containing it and preparation method therefor
11/18/2009	EP2119704A1 Acylguanidine derivative
11/18/2009	EP2119703A1 Novel indole derivative having inhibitory activity on i b kinase
11/18/2009	EP2119702A1 Amide derivative
11/18/2009	EP2119700A1 Benzylamine derivative or pharmaceutically acceptable acid addition salt thereof, and use thereof for medical purposes
11/18/2009	EP2119477A1 Composition for treatment of xerostomy or dry mouth
11/18/2009	EP2119476A2 Amide derivatives as positive allosteric modulators and methods of use thereof
11/18/2009	EP2119459A1 Treatment of neuropathy involving nitric oxide
11/18/2009	EP2119454A1 Pharmaceutical composition comprising porous dry matrix
11/18/2009	EP2119446A1 Epithelium improving agent
11/18/2009	EP2119444A1 Therapeutic agent for pain disease
11/18/2009	EP2119443A1 Composition for prevention or treatment of disease associated with thrombus or embolus
11/18/2009	EP2119442A1 Tacrolimus sustained release pharmaceutical composition
11/18/2009	EP2119441A1 Use of angiotensin II receptor antagonists in order to increase insulin sensitivity
11/18/2009	EP2119440A1 Amidino derivatives for use in the prevention or treatment of retinitis pigmentosa and Leber's disease
11/18/2009	EP2119439A2 Angiogenesis inhibitor for treating macular degeneration
11/18/2009	EP2119438A1 Bone metabolism ameliorating agent
11/18/2009	EP2119437A1 Device for the transdermal administration of bisoprolol
11/18/2009	EP2119436A1 Pharmaceutical compositions for preventing and treating eye pathologies
11/18/2009	EP2119435A1 Emollient composition
11/18/2009	EP2119434A1 Use of heterosidic flavonoid derivatives for therapy of stem cell cancers
11/18/2009	EP2118177A1 Imprinted polymers
11/18/2009	EP2118133A2 Amelioration of cellular stress response
11/18/2009	EP2118120A1 Nitric oxide releasing steroids
11/18/2009	EP2118118A2 Mediated cellular delivery of lna oligonucleotides
11/18/2009	EP2118117A2 Solid state forms of 5-azacytidine and processes for preparation thereof
11/18/2009	EP2118113A1 Pyridyl-triazolopyrimidine derivative or its salt, pesticide containing it and its production process

1 ... 2496 2497 2498 2499 2500 2501 2502 2503 2504 2505 2506 2507 2508 2509 2510 2511 2512 2513 2514 2515 2516 ... 7860